Suppr超能文献

酰基辅酶A胆固醇酰基转移酶抑制剂作为抗动脉粥样硬化药物:化合物与作用机制

ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms.

作者信息

Matsuda K

机构信息

Cardiovascular & Atherosclerosis Research Laboratories, Yamanouchi Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki Pref., Japan.

出版信息

Med Res Rev. 1994 May;14(3):271-305. doi: 10.1002/med.2610140302.

Abstract

Atherosclerosis is a major death cause in western industrialized countries. A diagnosing system, medical prevention, and treatment of atherosclerosis is not sufficient so far. A direct acting antiatherosclerotic agent is eagerly waited. ACAT inhibitor approach could provide such an agent. In the formation of atherosclerosis, cholesteryl esters, which are the lipids which accumulate in atheromatous plaques by an aid of macrophages and smooth muscle cells, forming foam cells, may play an important role. ACAT enzyme is responsible for the acylation of cholesterol to cholesteryl esters, a transformation which can be essential in not only cholesteryl esters accumulation at arterial walls but also the absorption of cholesterol in the intestine and the excretion of cholesterol in the liver. From these points, ACAT inhibitors might work against atherosclerosis in three different ways: first, cholesteryl ester accumulation inhibition at arterial walls could be a direct antiatherosclerotic effect; second, cholesterol absorption inhibition at the intestine; and third, cholesterol excretion acceleration at the liver, while the later two effects would result in a reduction of blood cholesterol level--a major risk factor of atherosclerosis. Taking account of this discussion, the ACAT inhibitors would be potent antiatherosclerotic agents. Medicinal research has been contributing full strength to produce an ultimate compound. These efforts should provide a drug which will be useful to patients.

摘要

动脉粥样硬化是西方工业化国家的主要死因。到目前为止,动脉粥样硬化的诊断系统、医学预防和治疗都还不够完善。人们急切地期待着一种直接作用的抗动脉粥样硬化药物。酰基辅酶A:胆固醇酰基转移酶(ACAT)抑制剂方法有望提供这样一种药物。在动脉粥样硬化的形成过程中,胆固醇酯(一种在巨噬细胞和平滑肌细胞的作用下在动脉粥样硬化斑块中积聚、形成泡沫细胞的脂质)可能起重要作用。ACAT酶负责将胆固醇酰化为胆固醇酯,这一转化不仅对动脉壁上胆固醇酯的积聚至关重要,而且对肠道中胆固醇的吸收和肝脏中胆固醇的排泄也必不可少。基于这些观点,ACAT抑制剂可能通过三种不同方式对抗动脉粥样硬化:第一,抑制动脉壁上胆固醇酯的积聚可产生直接的抗动脉粥样硬化作用;第二,抑制肠道对胆固醇的吸收;第三,加速肝脏中胆固醇的排泄,而后两种作用会导致血液胆固醇水平降低——动脉粥样硬化的一个主要危险因素。考虑到上述讨论,ACAT抑制剂可能是有效的抗动脉粥样硬化药物。药物研究一直在全力以赴研发出最终的化合物。这些努力应该会提供一种对患者有用的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验